Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
RZVTwMZcN5mHbacH
